Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 32651 total
Insider filings this week reveal a wave of selling at the top. Applied Materials CEO Gary Dickerson filed two separate sales totalling over $50M. He sold 50,332 shares at $700 and another 19,970 shares at $735. Both…
Short sellers are moving fast this week. CoreWeave saw its SI % of free float jump to 33.1%, up 4.8 percentage points in seven days. The AI cloud company only went public in March. Bears are already circling…
The week of July 12 is one of the busiest on the earnings calendar. Bank of America reports Tuesday before the open. BNY Mellon follows on Wednesday. Thursday brings the biggest prints: Netflix reports after the close,…
Q2 earnings season is now underway. Options traders are showing unusual caution ahead of a packed reporting calendar this week. UnitedHealth Group is drawing the most attention. The stock carries just 1.9% short…
Analyst desks stayed busy this week. Three sectors — airlines, specialty chemicals, and energy — saw the most notable moves. IFF collected an upgrade from analysts, pushing the consensus to a firmer buy tilt. The…
A wave of significant insider selling hit US markets this week, with filings disclosing hundreds of millions in stock disposals across several well-known names. The biggest story belongs to PRM. Windacre Partnership, a…
Short sellers moved aggressively this week. The data, running to July 9, shows clear targets. CRWV (CoreWeave) saw the biggest jump among large caps. SI % of free float climbed to 33.1%, up 4.8 percentage points in…
Q2 reporting kicks off in earnest this week. Bank of America reports Tuesday before the open. BNY Mellon follows Wednesday. Thursday brings the week's two biggest prints: Netflix after the close and UnitedHealth Group…
A packed earnings slate is shaping options sentiment this week. Eight S&P 500 names report by Thursday. Markets are watching closely. UNH kicks off Wednesday with one of the most closely scrutinised prints of the year.…
The Q2 earnings season heats up this week. Banks kick things off on Monday. Bank of America reports Q2 results before the open on Tuesday. The $423bn lender carries short interest of just 1.4% of free float. BNY Mellon…
BlackRock reports Q2 results on July 15 with options markets, analyst upgrades, and a firm stock price all pointing in the same direction — toward the bull case. The clearest pre-earnings signal comes from options,…
Alcoa heads into its July 15 Q2 earnings release with the Street's conviction visibly eroding and options traders rotating toward calls rather than puts — a divergence that makes the positioning unusually hard to…
Crown Castle heads into its July 15 Q2 earnings report with options traders unusually bullish and the stock rebounding sharply from a bruising month. The options market is the clearest signal of the current mood. The…
Analysts raised target prices across several large-cap names on Saturday. META saw its consensus target tick up to $828, with 56 buy ratings against zero sells. The social media giant carries just 1.4% short interest —…
KMI heads into its July 15 Q2 results with positioning broadly relaxed — bears have retreated and the lending market poses no friction for either side. Short sellers have been cutting exposure. Short interest has…
BNY heads into Tuesday's pre-market Q2 release with one notable shift since earlier previews: options positioning has grown meaningfully less defensive. The put/call ratio has dropped to 1.19, now running about one…
Elevance Health arrives at its July 15 Q2 print with analysts in a clear upgrading mood, but the stock has quietly given back ground since the previous article, putting the Street's conviction to the test. The most…
First Horizon Corporation reports Q2 earnings on July 15 with a notable tailwind: analysts have been quietly raising their targets in the days before the release. The most striking pre-earnings signal is the breadth of…
The past two weeks of insider filings reveal a clear split: most US insiders were selling, but one biotech chief kept buying aggressively. The biggest buyer is SMMT Summit Therapeutics CEO Bob Duggan, who filed a $50M…
TSM heads into its July 16 Q2 print with analyst conviction running higher than the stock price currently reflects. The most telling development of the past three weeks is a cluster of target-price raises that arrived…
